Top Story Today
Pharma Threw Every Constitutional Argument at Medicare Drug Pricing. None of Them Worked.
The Supreme Court refused to hear challenges from AstraZeneca, BMS, Novo Nordisk, and three other pharma giants, ending the industry's last legal shot at killing Medicare drug price negotiation. The scoreboard is staggering: 10 district courts, 6 appeals courts, and now the Supreme Court, all siding against the industry. The first batch of negotiated drugs already took effect in January with discounts of 38% to 79%, and the program keeps expanding every year. With an estimated $100 billion in industry revenue at stake over the next decade, boardrooms are pivoting hard toward biologics (which get 13 years before negotiation kicks in, versus 9 for pills) and front-loaded launch strategies designed to capture value fast.
Why it matters: With every legal avenue exhausted, IRA drug pricing is now a permanent feature of pharma's business landscape. The ripple effects are already reshaping R&D portfolios, M&A targets, and launch playbooks across the entire industry.
Read more →Science & Discovery
A Pig Kidney Kept a Man Alive for 271 Days. The FDA Wants to See More.
Tim Andrews spent nine months off dialysis thanks to a gene-edited pig kidney with 69 CRISPR modifications, the longest a xenotransplant has ever functioned in a living human. eGenesis now has FDA clearance for a Phase 1/2/3 trial, and a second patient has been dialysis-free for over 200 days. With 90,000 Americans on the kidney waiting list, the question has shifted from "can this work" to "how long can we make it last."
Read more →BioNTech's mRNA Cancer Vaccine Shrank Tumors in Patients Who'd Exhausted Every Option
An off-the-shelf mRNA vaccine (BNT111) combined with cemiplimab hit an 18.1% response rate in melanoma patients who had already failed PD-1 therapy, nearly doubling the historical benchmark. Median overall survival reached about 20.7 months. It's not a home run, but in a field littered with failed cancer vaccines, it's proof that mRNA can do more than prevent COVID.
Read more →One Blood Draw, Fifty Cancers, and a Whole Lot of Unanswered Questions
Exact Sciences launched Cancerguard, a $689 liquid biopsy test screening for 50-plus cancer types from a single blood draw. Specificity is solid at 97.4%, but early-stage sensitivity sits at just 39%. Insurance won't cover it, the FDA hasn't approved it, and no MCED test has yet proven it actually reduces cancer deaths. Promising tech, but very early innings.
Read more →Clinical & Competitive
UCB's Bimzelx Just Beat a $13 Billion AbbVie Franchise in a Head-to-Head Trial
In a roughly 553-patient head-to-head study, Bimzelx posted a 49.1% response rate versus 38.4% for AbbVie's Skyrizi on the primary joint endpoint in psoriatic arthritis. It's the first biologic ever to show superiority on a major joint measure against another advanced biologic in PsA. The result reframes the IL-17 vs. IL-23 debate and gives rheumatologists new data to rethink treatment algorithms.
Read more →Immunovant Paid $39 Million to Kill Its Own Drug (and That Was the Smart Move)
After two Phase 3 failures in thyroid eye disease, Immunovant spent $39 million unwinding batoclimab and is betting everything on its cleaner next-gen FcRn inhibitor, IMVT-1402. With $714 million in cash and roughly 10 autoimmune indications planned, the company is making a disciplined pivot in a crowded class where argenx already dominates.
Read more →Deals & Strategy
The $885 Million Verdict That Could Blow Up Pharma's Favorite Legal Loophole
A Boston jury hit Takeda with an $885 million pay-for-delay verdict over a 2014 deal to keep a generic constipation drug off shelves. Treble damages could push the total past $2.5 billion. It's the first plaintiff trial win on this theory in over a decade, and it signals that juries can see through the creative deal structures pharma adopted after the Supreme Court's 2013 Actavis ruling.
Read more →This Biotech Filed Its IPO the Day After Landing a $2.3 Billion Regeneron Deal
Parabilis Medicines announced a $2.3 billion Regeneron collaboration on a Monday, then filed its IPO on Tuesday. The deal covers Parabilis's cell-penetrating Helicon peptide platform, with $125 million in near-term cash and the rest in milestones. In a biotech IPO market that's barely thawed, the sequencing is a masterclass in building investor confidence.
Read more →The First PROTAC Drug Got Approved. Then Nobody Wanted to Sell It.
Arvinas and Pfizer built the first approved PROTAC drug (Veppanu for breast cancer), then realized neither wanted to commercialize it. A three-way deal hands global rights to Rigel Pharmaceuticals, whose specialty oncology sales force is a natural fit. For Rigel, it's a bet-the-company moment; for the PROTAC field, it's the first test of commercial viability.
Read more →Industry Watch
AI in Clinical Trials Is Scaling Bad Decisions, Not Solving Them
A new report warns that AI tools in clinical trials are amplifying biased datasets and reinforcing flawed site selection rather than fixing root problems. Over half of trials already miss enrollment timelines, and AI trained on skewed historical data is hardening those inequities at industrial scale. The takeaway: fix the process first, then add the turbocharger.
Read more →